A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia
- 21 October 2008
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 379 (3) , 241-251
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a major complication linked with the metabolic syndrome associated with dyslipidemia, inflammation, and oxidative stress. Impact of type 2 diabetes with hyperlipidemia in NAFLD has to be established, as well as the utility of commonly prescribed anti-diabetic and lipid-lowering agents in improving liver injury markers. Genetic type 2 diabetic Goto–Kakizaki rats were fed with a high-fat diet to test hepatic effects of type 2 diabetes with hyperlipidemia and the effect of atorvastatin and insulin, individually and in combination, in systemic and hepatic inflammatory and oxidative stress markers. High-fat diet aggravated fasting glycemia, systemic and liver lipids, and inflammatory and oxidative stress markers. Individual treatments improved glycemic and lipid profiles, but failed to improve inflammatory markers, whereas insulin was able to reduce liver oxidative stress parameters. Combination of insulin and atorvastatin further improved glycemic and lipid profiles and decreased circulating C-reactive protein levels and liver inflammatory and oxidative stress markers. Insulin and atorvastatin combination leads to better glycaemic and lipid profiles and to better protection against liver inflammation and oxidative stress, giving a superior level of liver protection in type 2 diabetic with hyperlipidemia.Keywords
This publication has 46 references indexed in Scilit:
- Hypoadiponectinemia Plays a Crucial Role in the Development of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus Independent of Visceral Adipose TissueAlcohol, Clinical and Experimental Research, 2007
- Time Course of C-Reactive Protein Reduction With Simvastatin Therapy in Patients With Type 2 Diabetes MellitusThe American Journal of Cardiology, 2006
- Acute Antiinflammatory Properties of Statins Involve Peroxisome Proliferator–Activated Receptor-α via Inhibition of the Protein Kinase C Signaling PathwayCirculation Research, 2006
- Effect of Low Doses of Atorvastatin on Adiponectin, Glucose Homeostasis, and Clinical Inflammatory Markers in Kidney Transplant RecipientsTransplantation Proceedings, 2005
- Assessing the Predictive Accuracy of QUICKI as a Surrogate Index for Insulin Sensitivity Using a Calibration ModelDiabetes, 2005
- Oxidative stress, ER stress, and the JNK pathway in type 2 diabetesJournal of Molecular Medicine, 2005
- Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-κB activationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2005
- HMG-CoA Reductase Inhibitors Do Not Improve Glucose Intolerance in Spontaneously Diabetic Goto-Kakizaki RatsBiological and Pharmaceutical Bulletin, 2005
- Effect of High Dietary Fat on Insulin Secretion in Genetically Diabetic Goto-Kakizaki RatsPancreas, 2002
- The role of TNFα in adipocyte metabolismSeminars in Cell & Developmental Biology, 1999